Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus PROVENTIL HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus PROVENTIL HFA.
ISOETHARINE MESYLATE vs PROVENTIL-HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP in bronchial smooth muscle, leading to bronchodilation.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
Inhalation: 1-2 inhalations (0.34 mg per actuation) via metered-dose inhaler every 4-6 hours as needed; or 0.25-0.5 mL of 1% solution diluted in 2-3 mL of normal saline via nebulizer every 4-6 hours.
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5–5 hours in adults after inhalation; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Primarily renal excretion of unchanged drug and metabolites (sulfate and glucuronide conjugates); approximately 40-50% excreted renally as unchanged drug within 24 hours, with the remainder as metabolites. Biliary/fecal excretion is minimal (<5%).
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist